Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
about
Plasma membrane transporters in modern liver pharmacologyRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patientsXanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistanceContribution of tumoral and host solute carriers to clinical drug response.The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.The role of transporters in the toxicity of nucleoside and nucleotide analogs.The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Drug transporter pharmacogenetics in nucleoside-based therapies.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.ABC transporters and their role in nucleoside and nucleotide drug resistance.Human ABCG2: structure, function, and its role in multidrug resistance.The cancer stem cell hypothesis: a guide to potential molecular targets.Recent studies of 5-fluorouracil resistance in pancreatic cancerLack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell linesMetabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.ABCG2/BCRP dysfunction as a major cause of gout.ABCG2 as a therapeutic target candidate for gout.Identification of ABCG2 dysfunction as a major factor contributing to gout.Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
P2860
Q26829263-DCDCE69E-C06D-4287-855B-23F4823A91E2Q26865927-F63DC6C7-8F1E-48C1-8120-3796336DBF2EQ28067499-9DB05771-24B6-4F3C-BCCE-75979E1C0226Q28535342-D3C6667F-366E-4DDB-9DC2-015D5F3131AAQ30364846-3BA8A4FD-7C45-4494-8FA5-F96E3D3D61B6Q33718767-E6DB74A6-9493-4AC7-8865-A20A527D39E3Q34159634-59C7B6C0-3E42-4932-97B3-336BA91EABC0Q34993085-ED69344A-E1EB-43A3-A856-4C4E9AA7008DQ35588356-493F5FCE-9B21-4D4C-A9A6-476E00B03A9EQ35776784-AB977C2A-6452-44BE-A4E3-FEBF519FEAEAQ35946876-2DDAD083-A41D-4AE9-8576-862437559CDBQ36374851-836CCDFD-A334-4D62-BABF-568EF36D16F6Q36921993-B08630EC-F5DD-4EE0-A508-7BDC86B9C34AQ36933169-10C14A97-EC0C-4430-B37A-1A64DFFC7D9CQ37422773-EA46416F-BEC1-4D6D-9436-91A361536759Q37424784-159DF019-6B34-4818-A3A9-E2686CCF2D4CQ37740126-1A868EFF-F5F9-46C5-90B7-060D27BC40AAQ37760954-C2110578-119B-476D-BA74-503593EE2DC5Q37963498-CA19A0A6-D764-408F-9E06-7688940EEA04Q37979617-31B55119-C93E-4AAE-8177-564E7EDDEA1BQ38003156-81EC3C34-1AA8-44C4-B9C9-CE7EF4B3087EQ38254181-D24408B9-FEC6-42F2-B0A2-2B0C0EED73C7Q38268619-D613FAC2-FF9C-4A5E-B812-3F6DD374F8DCQ38762107-94D7D577-811F-4F88-8BF3-76DF08C0B33CQ39094261-D0FBE95C-9855-4BC1-A47B-B28099392412Q39446984-36CA977E-BB18-46D4-B627-18DC2FB6D6EDQ39564395-67AF6A19-766B-4085-B320-7D9D2782C191Q42912844-D361A67B-2183-4019-865E-F3B5DB25A071Q43109279-1B1E5F11-F8B3-4FDC-83F5-2BE2B59670B8Q43136603-820037F0-9746-4924-A862-4FDDB80F2FB6Q46884058-B668362C-BF70-4547-ADE4-4D4998BB2015Q47770438-77803F21-DB4B-402F-9160-0565AF532001Q53201781-F1F44735-C13A-4759-95FB-0746BE44DC04Q55315083-2E03EBFD-D861-466E-ACE6-361F059685E0
P2860
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Contribution of the drug trans ...... gainst anticancer nucleosides.
@en
Contribution of the drug transporter ABCG2
@nl
type
label
Contribution of the drug trans ...... gainst anticancer nucleosides.
@en
Contribution of the drug transporter ABCG2
@nl
prefLabel
Contribution of the drug trans ...... gainst anticancer nucleosides.
@en
Contribution of the drug transporter ABCG2
@nl
P2093
P1476
Contribution of the drug trans ...... against anticancer nucleosides
@en
P2093
Cornelia de Wolf
Jos Beijnen
Koen van de Wetering
Marcel de Haas
Piet Borst
Robert Jansen
P304
P356
10.1158/1535-7163.MCT-08-0427
P577
2008-09-02T00:00:00Z